Metropolitan Life Insurance CO Aptinyx Inc. Transaction History

Metropolitan Life Insurance CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.99 - $19.33 $28,875 - $139,891	-7,237 Closed	0 $0
Q4 2018 Jul 13, 2023	BUY	$16.15 - $28.93 $116,877 - $209,366	7,237 New	7,237 $119,000
Q4 2018 Feb 14, 2019	BUY	$16.15 - $28.93 $91,279 - $163,512	5,652 Added 356.59%	7,237 $120,000
Q3 2018 Jul 13, 2023	BUY	$20.21 - $31.85 $146,259 - $230,498	7,237 New	7,237 $210 Million
Q3 2018 Nov 14, 2018	BUY	$20.21 - $31.85 $32,032 - $50,482	1,585 New	1,585 $46,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.